4BIO Capital

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.

RNA therapeutics designed to restore expression of silenced genes

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.